高通量浆液性卵巢癌患者循环肿瘤DNA中BRCA1/2胚系突变回复突变的检测
本研究对30例携带BRCA1/2胚系突变的高级别浆液性卵巢癌患者进行血浆游离DNA和肿瘤组织的靶向扩增子二代测序,以无偏方式检测回复突变。在复发患者肿瘤样本中检出5例回复突变,其中3例在cfDNA中检出。所有检出回复突变的患者均对铂类或PARP抑制剂耐药。
要点
- 复发患者肿瘤检出回复突变5/16例,cfDNA检出3/5例。
- 所有检出回复突变的患者对铂类或PARP抑制剂耐药。
- 回复突变等位基因频率和肿瘤DNA丰度影响检测灵敏度。
核心结论
- 回复突变可通过无偏分析在cfDNA中检出,提示其可能用于预测复发高级别浆液性卵巢癌的化疗反应。
研究设计与样本
- 研究纳入30例携带BRCA1或BRCA2胚系突变的高级别浆液性卵巢癌患者,分为初治减瘤术前(n=14)和疾病复发(n=16)两个队列。
- 多数患者(24/30)有配对的肿瘤和血浆样本,采用不依赖回复序列先验知识的靶向扩增子二代测序检测。
主要发现
- 5例患者检出预测可恢复BRCA1/2开放阅读框的基因内突变,其中2例有多个独立回复等位基因。
- 回复突变仅在复发患者肿瘤样本中检出(5/16),且仅在肿瘤检出回复突变的患者cfDNA中检出(3/5)。
- 对一例有多个独立回复突变患者的快速尸检提示,转移灶中回复等位基因频率是检测灵敏度的重要决定因素。
- 以TP53突变等位基因频率衡量的总cfDNA中肿瘤来源DNA丰度也影响检测灵敏度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Germline BRCA1 or BRCA2 mutations in patients with high-grade serous ovarian cancer (HGSC) are associated with favorable responses to chemotherapy. However, secondary intragenic (reversion) mutations that restore protein function lead to clinically significant rates of acquired resistance. The goal of this study was to determine whether reversion mutations could be found in an unbiased manner in circulating cell-free DNA (cfDNA) to predict treatment response in HGSC. Patients and Methods Plasma and tumor samples were obtained from 30 patients with HGSC with either BRCA1 or BRCA2 germline mutation. Two cohorts were ascertained: patients with a malignancy before undergoing primary HGSC debulking surgery (n = 14) or patients at disease recurrence (n = 16). Paired tumor and plasma samples were available for most patients (24 of 30). Targeted amplicon, next-generation sequencing was performed using primers that flanked germline mutations, whose design did not rely on prior knowledge of reversion sequences. Results Five patients were identified with intragenic mutations predicted to restore BRCA1/2 open reading frames, including two patients with multiple independent reversion alleles. Reversion mutations were only detected in tumor samples from patients with recurrent disease (five of 16) and only in cfDNA from patients with a tumor-detected reversion (three of five). Findings from a rapid autopsy of a patient with multiple independent reversions indicated that reversion-allele frequency in metastatic sites is an important determinant of assay sensitivity. Abundance of tumor-derived DNA in total cell-free DNA, as measured by TP53 mutant allele frequency, also affected assay sensitivity. All patients with reversions detected in tumor-derived DNA were resistant to platin- or poly ADP ribose polymerase inhibitor-based chemotherapy. Conclusion Reversion mutations can be detected in an unbiased analysis of cfDNA, suggesting clinical utility for predicting chemotherapy response in recurrent HGSC.
引用
- Christie EL, Fereday S, Doig K, et al. Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer. J Clin Oncol. 2017. PMID: 28414925. doi:10.1200/JCO.2016.70.4627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。